Financial Advisory Corp bought a new stake in shares of Stryker Co. (NYSE:SYK - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 862 shares of the medical technology company's stock, valued at approximately $310,000.
Other institutional investors have also bought and sold shares of the company. Lakeshore Capital Group Inc. purchased a new stake in Stryker during the fourth quarter valued at $850,000. Heck Capital Advisors LLC bought a new stake in shares of Stryker in the 4th quarter worth about $662,000. Integrated Advisors Network LLC lifted its holdings in shares of Stryker by 5.5% in the 4th quarter. Integrated Advisors Network LLC now owns 3,415 shares of the medical technology company's stock worth $1,230,000 after acquiring an additional 178 shares during the last quarter. Hall Capital Management Co. Inc. bought a new stake in shares of Stryker in the 4th quarter worth about $432,000. Finally, Liberty Square Wealth Partners LLC bought a new stake in shares of Stryker in the 4th quarter worth about $226,000. Hedge funds and other institutional investors own 77.09% of the company's stock.
Stryker Stock Up 0.5%
Shares of SYK stock traded up $1.73 during trading hours on Thursday, reaching $382.12. 840,274 shares of the stock were exchanged, compared to its average volume of 1,340,241. The business's fifty day moving average is $368.42 and its two-hundred day moving average is $376.23. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The firm has a market capitalization of $145.85 billion, a P/E ratio of 49.24, a P/E/G ratio of 2.93 and a beta of 0.93. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19.
Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.73 by $0.11. The firm had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The company's revenue for the quarter was up 11.9% on a year-over-year basis. During the same period last year, the company earned $2.50 earnings per share. As a group, research analysts expect that Stryker Co. will post 13.47 EPS for the current fiscal year.
Stryker Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date is Monday, June 30th. Stryker's payout ratio is currently 45.41%.
Wall Street Analyst Weigh In
Several research analysts recently commented on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $442.00 price target on shares of Stryker in a research note on Friday, March 21st. The Goldman Sachs Group set a $422.00 price target on shares of Stryker in a research note on Tuesday, March 4th. Roth Mkm raised their target price on shares of Stryker from $405.00 to $456.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Sanford C. Bernstein set a $450.00 target price on shares of Stryker in a research report on Monday, May 5th. Finally, Canaccord Genuity Group lifted their price objective on shares of Stryker from $420.00 to $435.00 and gave the stock a "buy" rating in a research report on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $427.30.
Read Our Latest Analysis on SYK
Insider Activity at Stryker
In related news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the sale, the director now owns 3,417,326 shares of the company's stock, valued at $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 5.20% of the company's stock.
About Stryker
(
Free Report)
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Featured Articles
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
